Incyte Corp (INCY) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Promising ... [Yahoo! Finance]
Incyte Corporation (INCY)
Last incyte corporation earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
incyte.com/ir/investor-overview.aspx
Company Research
Source: Yahoo! Finance
Jakafi Sales: $758 million, up 7% year-over-year. Opzelura Sales: $143 million, up 20% versus prior year. Hematology and Oncology Net Sales: $204 million, up 116% year-over-year. GAAP R&D Expenses: $516 million, increasing 18% from the prior year. GAAP SG&A Expenses: $328 million, increasing 1% year-over-year. Full Year 2026 Total Net Sales Guidance: $4.77 billion to $4.94 billion, representing a 10% to 13% increase from the prior year. Jakafi Full Year Sales Guidance: $3.22 billion to $3.27 billion. Opzelura Full Year Sales Guidance: $750 million to $790 million. Hematology and Oncology Products Full Year Sales Guidance: $800 million to $880 million. Total GAAP R&D and SG&A Operating Expenses Guidance: $3.495 billion to $3.675 billion for the full year. Cost of Sales: Expected to remain stable at approximately 9% of net sales. Warning! GuruFocus has detected 4 Warning Sign with OPRA. Is INCY fairly valued? Test your thesis with our free DCF calculator. Rele
Show less
Read more
Impact Snapshot
Event Time:
INCY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INCY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INCY alerts
High impacting Incyte Corporation news events
Weekly update
A roundup of the hottest topics
INCY
News
- Incyte (INCY) had its price target raised by Stifel Nicolaus from $120.00 to $123.00. They now have a "buy" rating on the stock.MarketBeat
- Earnings To Watch: Amgen (AMGN) Reports Q1 Results Tomorrow [Yahoo! Finance]Yahoo! Finance
- Incyte (INCY) had its "market perform" rating reaffirmed by Oppenheimer Holdings, Inc..MarketBeat
- Incyte to Present at Upcoming Investor ConferencesBusiness Wire
- Incyte (INCY) Beats Q1 Earnings and Revenue Estimates [Yahoo! Finance]Yahoo! Finance
INCY
Earnings
- 4/28/26 - Beat
INCY
Sec Filings
- 4/28/26 - Form DEFA14A
- 4/28/26 - Form ARS
- 4/28/26 - Form DEF
- INCY's page on the SEC website